This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Cell Therapeutics

Cell Therapeutics' (CTIC - Get Report) latest fund-raising Wednesday night brought in a few emails, including Tanya D., who wrote to say, "I guess you were right about Cell Therapeutics needing to raise more money. But I don't understand why they would do it now with fast-track status for pixantrone coming so soon."

Cell Therapeutics sold 29.3 million shares in an overnight deal priced at $1.30, or a 20% discount to the Wednesday close. The deal included 25% warrant coverage, which means buyers got one warrant (priced at $1.70) for every four shares of stock they bought. The warrants are a common sweetener used by underwriters (in this case Rodman & Renshaw) to induce clients to participate in the deal.

Total gross proceeds from this follow-on offering: $38.1 million.

That's money badly needed by Cell Therapeutics, which is apparent to any investor who can even skim a balance sheet. I realize that most retail investors owning or interested in Cell Therapeutics focus on the cancer drug pixantrone, but you cannot ignore the perils of the company's balance sheet.

The recent debt tender offer improved Cell Therapeutics' financial health somewhat (and so does this latest financing) but the company is still burning cash, still has debt on the books, and will probably need to raise even more money in the future.

Tanya raises a good point about the timing of this recent fund-raising. The Food and Drug Administration will inform Cell Therapeutics next month whether the agency will grant pixantrone a six-month review. Pixantrone is a cancer drug. Almost all cancer drugs get a six-month review, so I'd only be surprised if the FDA decides to take more time.
1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
CTIC $0.47 -7.33%
CRIS $1.92 -4.48%
HEB $0.14 2.37%
AAPL $95.18 1.64%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs